Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03247413 · ClinicalTrials.gov registry record · Phase 4
Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation
A Phase 4 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 63
- Enrollment target
NCT03247413: Clinical Trial Phase 4 study, sponsored by Johns Hopkins University.
NCT03247413 is a Phase 4 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03247413, a Phase 4 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 63 participants
- Enrollment target
Study Summary
Chronic neck and back pain has become one of the leading causes of disability and loss of productivity. For many patients with facet or sacroiliac joint mediated pain who have responded to diagnostic nerve blocks, radiofrequency ablation of the nerves innervating the joints can provide long term relief. Radiofrequency ablation (RFA) is a relatively safe procedure with minimal risk of adverse events. However, with any procedure involving damage to the peripheral nervous system, there is risk of post-procedure neuropathic pain. The investigators will test the hypothesis that dexamethasone injection delivered at the time of lesion effectively prevents the development of post-ablation neuritis through a placebo-controlled, double-blind, randomized trial in patients undergoing cervical, thoracic, lumbar, and sacroiliac joint radiofrequency denervations
Interventions
- DRUG Normal saline
- DRUG Dexamethasone 4 mg/ml
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2022-10-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03247413
The ClinicalTrials.gov registry entry for NCT03247413 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT03247413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03247413 about?
NCT03247413 is a clinical study titled "Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation". Chronic neck and back pain has become one of the leading causes of disability and loss of productivity. For many patients with facet or sacroiliac joint mediated pain who have responded to diagnostic nerve blocks, radiofrequency ablation of the nerves innervating the joints can provide long term rel...
What is the current status of trial NCT03247413?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 63 participants. The study started on 2019-09-01. Estimated completion is 2022-10-14.
What interventions are being tested in trial NCT03247413?
The interventions under investigation include: Normal saline (DRUG), Dexamethasone 4 mg/ml (DRUG).
Who is sponsoring clinical trial NCT03247413?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.